Leqembi
Eisai Investing up to $15M in Alzheimer's Dx Firm C2N
The investment will support efforts to expand the availability and use of C2N's blood-based biomarker tests for Alzheimer's disease in the US.
The €21 million effort led by Norway's Stavanger University Hospital is collecting genomic, proteomic, and other data on roughly 4,000 individuals.
Many firms in the space have developed or are developing tests for the marker, which shows great promise for detecting brain amyloid pathology.
Alzheimer's Dx Firms Aim to Take Advantage of Increased Testing Demand Following Leqembi Approval
Premium
Near term, CSF assays and PET imaging will likely remain the methods of choice for evaluating patients for the drug, but blood tests continue to gain traction.